Skip to main content
SpringerLink
Log in

BRONJ: The Future

  • Chapter
  • First Online:
Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach

  • 1443 Accesses

Abstract

Bisphosphonates are a class of agents that are widely used in the management of metastatic disease to the bone and in diseases of altered bone-turnover. Despite these benefits, bisphosphonate-related osteonecrosis of the jaw (BRONJ) has emerged as a complication that has afflicted a subset of patients receiving these drugs for the treatment of osteoporosis and metastatic bone cancer. The risk of developing this complication appears to be related to the potency of the bisphosphonate, the duration of exposure, and dentoalveolar trauma. Stage-specific management strategies have been developed as well as guidelines for evaluating the potential risks associated with this complication. In the past few years, based on the results of in vivo and in vitro research, there has been significant progress toward understanding osteonecrosis of the jaw. This chapter provides a review of the evolving strategies for the diagnosis, prevention, and management of BRONJ. New insights regarding the pathogenesis and treatment of this complication are discussed, as are the future challenges associated with the new drug regimens that have recently emerged for the treatment of osteoporosis and cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Marx R (2003) Pamidronate (Aredia) and zolendronate (Zometa) induced vascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

    Article  PubMed  Google Scholar 

  2. Ruggiero S, Mehrotra B, Rosenberg T (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  3. Bi Y, Gao Y, Ehirchiou D et al (2010) Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol 177:280–290

    Article  PubMed  CAS  Google Scholar 

  4. Kikuiri Y, Kim I, Yamaza T et al (2010) Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 25:1668–1679

    Article  PubMed  CAS  Google Scholar 

  5. Hokugo A, Christensen R, Chung EM et al (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 25:1337–1349

    Article  PubMed  CAS  Google Scholar 

  6. Lopez-Jornet P, Camacho-Alonso F, Molina-Miñano F et al (2010) An experimental study of bisphosphonate-induced jaw necrosis in Sprague-Dawley rats. J Oral Pathol Med 31:31

    Google Scholar 

  7. Maahs M, Azambuja A, Campos MM, Salum FG et al (2010) Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. Head Neck 29:29

    Google Scholar 

  8. Allen M, Burr D (2008) Mandible matrix necrosis in beagle dogs following 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66:987–994

    Article  PubMed  Google Scholar 

  9. Burr D, Allen M (2009) Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofacial Res 12:221–228

    Article  CAS  Google Scholar 

  10. Allen M, Kubek D, Burr D, Ruggiero S (2010) Compromised osseous healing of dental extraction sites in zolendronic acid-treated dogs. Osteoporos Int 22(2):693–702

    Article  PubMed  Google Scholar 

  11. Wood J, Bonjean K, Ruetz S (2002) Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharm Exper Ther 302:1055–1061

    Article  CAS  Google Scholar 

  12. Fournier P, Boissier S, Filleur S, Guglielmi J et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544

    PubMed  CAS  Google Scholar 

  13. Deckers M, Van Beek E, Van Der Pluijm G et al (2002) Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 17:998

    Article  PubMed  Google Scholar 

  14. Landesberg R, Cozin M, Cremers S, Woo V et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847

    Article  PubMed  Google Scholar 

  15. Otto S, Pautke C, Opelz C, Westphal I et al (2010) Osteonecrosis of the jaw: effect of BP type, local concentration, and acid milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837–2845

    Article  PubMed  Google Scholar 

  16. Sarasquete M (2008) BRONJ is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide analysis. Blood 111:2709

    Article  Google Scholar 

  17. Dodson T (2009) Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(Suppl 1):44–52

    Article  PubMed  Google Scholar 

  18. Stopeck A, Body J, Fujiwara Y (2009) Denosumab versus zolendronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer Suppl 7(2):2–3

    Article  Google Scholar 

  19. Aghaloo T, Felsenfeld A, Tetradis S (2010) Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 68:959–963

    Article  PubMed  Google Scholar 

  20. Taylor K, Middlefell L, Mizen K (2010) Osteonecrosis of the jaws induced by anti-RANK lingand therapy. Br J Oral Maxillofacial Surg 48:221–223

    Article  CAS  Google Scholar 

  21. Ruggiero S, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endond 102:433–441

    Article  Google Scholar 

  22. Surgeons AAOMS (2007) Position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 3:369–376

    Google Scholar 

  23. Ruggiero S, Dodson TB, Assael LA et al (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 67:2–12

    PubMed  Google Scholar 

  24. Marx R, Sawatari Y, Fortin M (2005) Bisphosphonate-induced exposed bone (Osteonecrosis\osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63:1567–1575

    Article  PubMed  Google Scholar 

  25. Durie B, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates (Letter). N Engl J Med 353:99

    Article  PubMed  CAS  Google Scholar 

  26. Badros A, Weikel D, Salama A (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952

    Article  PubMed  CAS  Google Scholar 

  27. Hoff A, Toth B, Altundag K (2006) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 24:8528

    Google Scholar 

  28. Bagan J, Jimenez Y, Gomez D, Sirera R (2008) Collagen telopeptide (serum CTX) and its relationship with size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 44:1088–1089

    Article  PubMed  CAS  Google Scholar 

  29. Kunchur R, Need A, Hughes T, Goss A (2009) Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate -associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167–1173

    Article  PubMed  Google Scholar 

  30. Kwon Y, Kim D, Obe J, Yoo J (2009) Correlation between serum C-terminal cross-linking telopeptide of type 1 collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:2644–2648

    Article  PubMed  Google Scholar 

  31. Lehrer S et al (2008) Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Path Oral Radiol Endod 106:389–391

    Article  Google Scholar 

  32. Marx R, Cillo J, Ulloa J (2007) Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410

    Article  PubMed  Google Scholar 

  33. Rosen H, Moses AC, Garber J et al (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103

    Article  PubMed  CAS  Google Scholar 

  34. Rosen H, Moses AC, Garber J, Ross DS et al (1998) Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 63:363–368

    Article  PubMed  CAS  Google Scholar 

  35. Treister N, Friedland B, Woo S (2010) Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Path oral Radiol Endod 109:753–764

    Article  Google Scholar 

  36. Arce K, Assael L, Weissman J, Markiewitz M (2009) Imaging findings in bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(Suppl 1):75–84

    Article  PubMed  Google Scholar 

  37. Chiandussi S, Biasotto M, Cavalli F et al (2006) Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofacial Radiol 35:236–243

    Article  CAS  Google Scholar 

  38. O’Ryan F, Khoury S, Liao W, Han M (2009) Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as a n early indicator. J Oral Maxillofac Surg 67:1363–1372

    Article  PubMed  Google Scholar 

  39. Carlson E, Basile J (2009) The role of surgical resection in the management of bisphosphonate-relatred osteonecrosis of the jaws. J Oral Maxillofac Surg 67(Suppl 1):85–95

    Article  PubMed  Google Scholar 

  40. Mucke T, Koschinski J, Deppe H, Wagenpfeil S et al (2010) Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Oncol. doi:10.1007/s00432-010-0953-1

  41. Stockman P, Vairaktaris E, Wehrhan F et al (2009) Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Cancer Care 18:449–460

    Article  Google Scholar 

  42. Frieberger J (2009) Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(Suppl 1):96–106

    Article  Google Scholar 

  43. Sabino M (2007) Efficacy of hyperbaric oxygen therapy in bisphosphonate-related osteonecrosos of the jaw. J Oral Maxillofac Surg 65:S41

    Article  Google Scholar 

  44. Curi M, Cossolin GS, Henrique Koga D et al (2007) Treatment of avascular necrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 65:349–355

    Article  PubMed  Google Scholar 

  45. Lee C, David T, Nishime M (2007) Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantology 32:371–382

    Article  Google Scholar 

  46. Harper R, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low -dose parathyroid hormone [rhPTH(1–340]. J Oral Maxillofac Surg 65:573–580

    Article  PubMed  Google Scholar 

  47. Bashutski J, Eber R, Kinney J, Benavides E et al (2010) Teriparitide and osseous regeneration in the oral cavity. N Engl J Med 363(25):2396–2405

    Article  PubMed  CAS  Google Scholar 

  48. Marx R (2009) Reconstruction of defects caused by bisphosphonate induced osteonecrosis of the jaws. J Oral Maxillofac Surg 67:107–119

    Article  PubMed  Google Scholar 

  49. Herford A, Boyne P (2008) Reconstruction of mandibular continuity defects with bone morphogenic protein-2 (rhBMP-2). J Oral Maxillofac Surg 66:616–624

    Article  PubMed  Google Scholar 

  50. Badros A, Evangelos T, Goloubeva O, Meiller T et al (2007) Long-term follow-up of multiple myeloma patients with osteonecrosis of the jaw. Blood 110(11):1030A–1031A

    Google Scholar 

  51. Dimopoulos M, Kastritis E, Bamia C, Melakopoulis I et al (2007) Decreased incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid after application of preventive measures. Blood 110(11):1056A

    Google Scholar 

  52. Mehrotra B, Fantasia J, Ruggiero S (2008) Outcomes of bisphosphonate related osteonecrosis of the jaw. Importance of staging and management guidelines. A large single institutional update. J Clin Oncol 26(Suppl):322

    Google Scholar 

  53. Grbic J et al (2010) The incidence of osteonecrosis of the jaw in patients receiving 5 mgs of zolendronic acid. Data from the health outcomes and reduced incidence with zolendronic acid once yearly clinical trials program. JADA 141:1365–1370

    PubMed  CAS  Google Scholar 

  54. Grbic J, Landesberg R, Lin S (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zolendroic acid once yearly. JADA 139:32–40

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York Center for Orthognathic and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Lake Success, NY, USA

    Salvatore L. Ruggiero

Authors
  1. Salvatore L. Ruggiero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salvatore L. Ruggiero .

Editor information

Editors and Affiliations

  1. , Dental Department, University of Messina, Via Consolare Valeria 1, Messina, 98100, Italy

    Francesco Saverio De Ponte

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Milan

About this chapter

Cite this chapter

Ruggiero, S.L. (2012). BRONJ: The Future. In: De Ponte, F. (eds) Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-2083-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2083-2_15

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2082-5

  • Online ISBN: 978-88-470-2083-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation